![A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors | Journal of Nuclear Medicine A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/62/10/1398/F1.large.jpg)
A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors | Journal of Nuclear Medicine
![Blood Journal on X: "A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia https://t.co/lJNxpqQqXK https://t.co/7OcnMKLAjT" / X Blood Journal on X: "A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia https://t.co/lJNxpqQqXK https://t.co/7OcnMKLAjT" / X](https://pbs.twimg.com/media/EclA2eGXYAE9HOs.png:large)
Blood Journal on X: "A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia https://t.co/lJNxpqQqXK https://t.co/7OcnMKLAjT" / X
![Protocol of a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA) | Neurological Research and Practice | Full Text Protocol of a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA) | Neurological Research and Practice | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs42466-019-0038-9/MediaObjects/42466_2019_38_Fig2_HTML.png)
Protocol of a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA) | Neurological Research and Practice | Full Text
![A 24‐Week, Phase IIa, Randomized, Double‐Blind, Placebo‐Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis - Khanna - 2023 - Arthritis & Rheumatology - Wiley Online Library A 24‐Week, Phase IIa, Randomized, Double‐Blind, Placebo‐Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis - Khanna - 2023 - Arthritis & Rheumatology - Wiley Online Library](https://acrjournals.onlinelibrary.wiley.com/cms/asset/42a9bbfa-0a1d-492b-a993-03d696724f84/art42477-toc-0001-m.jpg?trick=1696346236522)
A 24‐Week, Phase IIa, Randomized, Double‐Blind, Placebo‐Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis - Khanna - 2023 - Arthritis & Rheumatology - Wiley Online Library
![ELAMIPRETIDE IN PATIENTS WITH BARTH SYNDROME: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL FOLLOWED BY 36-WEEK OPEN-LABEL EXTENSION | Journal of the American College of Cardiology ELAMIPRETIDE IN PATIENTS WITH BARTH SYNDROME: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL FOLLOWED BY 36-WEEK OPEN-LABEL EXTENSION | Journal of the American College of Cardiology](https://www.jacc.org/cms/asset/f707f216-ce39-4329-bc3c-2f088569dc01/s0735-1097(20)31584-9.fp.png)
ELAMIPRETIDE IN PATIENTS WITH BARTH SYNDROME: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL FOLLOWED BY 36-WEEK OPEN-LABEL EXTENSION | Journal of the American College of Cardiology
![Design of the randomized, double-blind, controlled, cross-over study in... | Download Scientific Diagram Design of the randomized, double-blind, controlled, cross-over study in... | Download Scientific Diagram](https://www.researchgate.net/publication/237241329/figure/fig1/AS:299478704771073@1448412695171/Design-of-the-randomized-double-blind-controlled-cross-over-study-in-which-subjects.png)
Design of the randomized, double-blind, controlled, cross-over study in... | Download Scientific Diagram
![A Failed 6-Week, Randomized, Double-Blind, Placebo-Controlled Study of Once-Daily Extended Release Quetiapine Fumarate in Patients with Acute Schizophrenia: Lessons Learned - MedWorks Media A Failed 6-Week, Randomized, Double-Blind, Placebo-Controlled Study of Once-Daily Extended Release Quetiapine Fumarate in Patients with Acute Schizophrenia: Lessons Learned - MedWorks Media](https://medworksmedia.com/wp-content/uploads/2017/10/Cover-2-5-2.png)
A Failed 6-Week, Randomized, Double-Blind, Placebo-Controlled Study of Once-Daily Extended Release Quetiapine Fumarate in Patients with Acute Schizophrenia: Lessons Learned - MedWorks Media
![A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-α Antagonist | The A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-α Antagonist | The](https://www.jrheum.org/content/jrheum/41/11/2120/F1.large.jpg)
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-α Antagonist | The
![A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder.](https://dukespace.lib.duke.edu/dspace/bitstream/handle/10161/24821/Cusin_Perlis-2013_Double-blind%2C%20placebo-controlled%20trial%20of%20pramipexole%20augmentation%20in%20treatment-resistant%20major%20depressive%20disorder.pdf.jpg?sequence=4&isAllowed=y)
A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder.
![A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine](https://biblio.ugent.be/publication/8769973/file/01GJFQRZDTV3DNZKM310ZA861F/thumbnail.png)
A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine
![Why double-blind randomized trials are so powerful: everything you need to know in 5 minutes - YouTube Why double-blind randomized trials are so powerful: everything you need to know in 5 minutes - YouTube](https://i.ytimg.com/vi/oQt8jR5RgVQ/hqdefault.jpg)
Why double-blind randomized trials are so powerful: everything you need to know in 5 minutes - YouTube
![Prospective, Randomized, Double-blind, Placebo-controlled, Pilot Study of Extracorporeal Shock Wave Therapy for Detrusor Underactivity/Underactive Bladder - European Urology Focus Prospective, Randomized, Double-blind, Placebo-controlled, Pilot Study of Extracorporeal Shock Wave Therapy for Detrusor Underactivity/Underactive Bladder - European Urology Focus](https://www.eu-focus.europeanurology.com/cms/asset/add3606c-2ce8-4fa1-ba24-9920861ddabc/gr1.jpg)
Prospective, Randomized, Double-blind, Placebo-controlled, Pilot Study of Extracorporeal Shock Wave Therapy for Detrusor Underactivity/Underactive Bladder - European Urology Focus
![A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia: Molecular Therapy A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia: Molecular Therapy](https://www.cell.com/cms/attachment/f7119006-e9eb-45cc-a48a-f2878fe07e4a/gr1.jpg)
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia: Molecular Therapy
![Aspire: A 52-week, Muticenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, & Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) As Maintenance Treatment in Patients w/ Schizophrenia ... Aspire: A 52-week, Muticenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, & Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) As Maintenance Treatment in Patients w/ Schizophrenia ...](https://m.media-amazon.com/images/I/718temOaLoL._AC_UF1000,1000_QL80_.jpg)
Aspire: A 52-week, Muticenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, & Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) As Maintenance Treatment in Patients w/ Schizophrenia ...
![The Effectiveness of Hearing Aids and Two Service-Delivery Models in Older Adults: A Randomized Double-Blind, Placebo-Controlled Clinical Trial | The Hearing Review The Effectiveness of Hearing Aids and Two Service-Delivery Models in Older Adults: A Randomized Double-Blind, Placebo-Controlled Clinical Trial | The Hearing Review](https://hearingreview.com/wp-content/uploads/2017/05/HumesFig1-1000x640.jpg)